Is this you?
Request access for Options Research Group with your @optionsresearchgroup.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Options Research Group
Unclaimed profileSMO · Indiana & Arizona · ~8 sites
Intera lens
ICP 6Lift (cardio sample) 0.05Recruit soph 0.57
Quality Scorecard (1–100)
Overall62Recruit62Ops68Sponsor60Ther57
Performance (observed)
Historical trials
127
Completed
80
Terminated/Withdrawn
23
Completion rate
78%
Active now
21
Phase 2
37
Phase 3
77
Realized enrollment
218,476
First study year
2001
Years active
24
Match confidence
high
Enrollment velocity (inf)
9,103
Therapeutic
Areas
Dermatology, ENT, Pediatrics, Ophthalmology, Primary Care, Specialty, Acute Care (15+ therapeutic areas)
Breadth (conditions)
97
Languages
English
States
IN, AZ
Recruitment (web observed)
Trial Finder
Yes
Patient database
Y
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Top enroller status in pediatric migraine trials; operational efficiency messaging
Capability notes
Full-service trial operations; recruitment advertising; regulatory and IRB coordination; data entry and management; patient access to underrepresented populations
Relationships
Sponsors
AbbVie; Pfizer; Gilead Sciences; Takeda; Bristol-Myers Squibb; Allergan
CROs
Acrotech Biopharma Inc.; IQVIA Pty Ltd; Medpace, Inc.; PRA Health Sciences; Parexel; Premier Research
Owner / parent
Independently owned; physician-led (Maureen Banning founder/director); founded 2023 in current structure
Funding
Independently owned and physician-led
Expansion
8 sites across Indiana and Arizona; new Peoria, AZ location
Capacity & people
Investigators
—
Coordinators
—
CEO
Ryan Banning
VP Clinical Ops
Maureen Banning, RN, CCRC
VP Site Ops
Jason Babcock
VP Recruitment
Unknown
Emails
Unknown
Tech & DCT
CTMS
SiteCentric CTMS
eSource
Yes
Builds tech
Vendors
Tech stack
Microsoft 365; eSource platform
Recruiting visible
Y
Notes
Physician-led 8-site network across IN/AZ with 30+ years combined team experience. Founded 2023. Proven enrollment performance (top worldwide enrollers in pediatric migraine trials). Full-service operations reduce investigator burden. Growing network with expansion planned. Good recruitment advertising.
Recommendation features (sample indication)
Ind fit 0.12Liftability 0.05Overall62
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.